Ivabradine Anpharm

Ivabradine, the active ingredient in Ivabradine Anpharm, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for chronic heart failure and stable angina pectoris in adult patients. The medication is marketed within the European Union and conforms to relevant regulatory requirements.

GNH USA supplies Ivabradine Anpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality through rigorous manufacturing practices and provides reliable distribution to healthcare facilities across multiple continents, offering consistent product availability and comprehensive technical support.

Ivabradine acts on the cardiac sinus node to lower heart rate, benefiting conditions where heart rate reduction improves outcomes. - Chronic heart failure: improves symptoms and reduces the risk of hospitalization by decreasing myocardial oxygen demand. - Stable angina pectoris: lessens the frequency of angina attacks through heart rate reduction without affecting contractility. - Patients intolerant to beta‑blockers: provides an alternative mechanism for heart rate control when beta‑blockers are unsuitable.

Ivabradine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena, often described as bright spots or flashes, typically occurring in low‑light conditions and usually resolving without intervention. - Bradycardia: heart rate falls below the intended therapeutic range, which may cause fatigue, dizziness, or fainting if severe. - Headache: mild to moderate intensity, may be intermittent or persistent during treatment.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical attention: may present with profound fatigue, syncope, or hemodynamic compromise. - Atrial fibrillation or other significant arrhythmias: irregular heart rhythm that can increase the risk of stroke or require additional therapy. - Severe hypotension or heart block: marked drop in blood pressure or conduction disturbances that may necessitate hospitalization.

When prescribing Ivabradine, clinicians should observe several precautions to ensure patient safety. - Cardiac monitoring: assess resting heart rate before initiation and periodically during therapy. - Contraindications: avoid use in patients with severe hypotension, sick sinus syndrome, or acute decompensated heart failure. - Drug interactions: do not combine with strong CYP3A4 inhibitors or other bradycardic agents without careful supervision. - Hepatic impairment: use with caution and consider dose adjustment in moderate to severe liver disease. - Pregnancy and lactation: safety has not been established; use only if the potential benefit justifies the risk. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Ivabradine’s pharmacokinetics can be altered by several concomitant medicines, requiring attention to avoid adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole): may markedly increase ivabradine plasma concentrations. - Co‑administration with other heart‑rate‑lowering drugs (beta‑blockers, digoxin, diltiazem, verapamil): can cause excessive bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may raise ivabradine levels modestly. - CYP2C9 inhibitors (e.g., fluoxetine, amiodarone): can affect metabolism and require monitoring. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine efficacy.